Assess whether a CMO finding is a delay or a refuse-to-file risk (9108f9)

Situation

FDA Response and Labeling work in a labeling team facing a boxed-warning debate now turns on a CMO finding is because an inspector asking for batch records you cannot produce this week put inspection-readiness findings at a CMO in play. CMC change-control owner should say what inspection-readiness findings at a CMO proves.

Decision

CMC change-control owner in a labeling team facing a boxed-warning debate must choose A CMO finding is a delay / A refuse-to-file risk using inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• Authorize A CMO finding is a delay now; inspection-readiness findings at a CMO already has the discriminator after an inspector asking for batch records you cannot produce this week.
• Keep A refuse-to-file risk in force until inspection-readiness findings at a CMO is completed after an inspector asking for batch records you cannot produce this week for CMC change-control owner.
• Treat inspection-readiness findings at a CMO as A CMO finding is a delay because both readings appear after an inspector asking for batch records you cannot produce this week.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page a CMO finding is turns on in inspection-readiness findings at a CMO.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether inspection-readiness findings at a CMO supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read inspection-readiness findings at a CMO against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMO finding is for CMC change-control owner.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / FDA Response and Labeling packet (inspection-readiness findings at a CMO after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for CMC change-control owner in a labeling team facing a boxed-warning debate.